Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: Introducing the prostate cancer consortium in Europe

European Urology

Volumn 67, Issue 5, 2015, Pages 904-912

  Fizazi, Karim ^a   Abrahamsson, Per Anders ^b,c   Ahlgren, Goran ^b,c   Bellmunt, Joaquim ^d   Castellano, Daniel ^e   Culine, Stephane ^f   De Wit, Ronald ^g   Gillessen, Silke ^h   Gschwend, Juergen E ⁱ   Hamdy, Freddie ^j   James, Nicholas ^k   McDermott, Raymond ^l   Miller, Kurt ^m   Wiegel, Thomas ⁿ   Wirth, Manfred ^o   Tombal, Bertrand ^p  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LUND UNIVERSITY   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f SAINT LOUIS HOSPITAL   (France)

^g ERASMUS MC CANCER INSTITUTE   (Netherlands)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF WARWICK   (United Kingdom)

^l ADELAIDE AND MEATH HOSPITAL   (Ireland)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ UNIVERSITY HOSPITAL ULM   (Germany)

^o UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^p UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

more..

Author keywords

Clinical research; European consortium; Phase 3 trials

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; CABAZITAXEL; ENZALUTAMIDE; PREDNISONE; RADIUM 223; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CASTRATION RESISTANT PROSTATE CANCER; EUROPE; HUMAN; MEDICAL ONCOLOGIST; ONCOLOGIST; PELVIS LYMPH NODE; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION ONCOLOGIST; REVIEW; TREATMENT DURATION; UROLOGIST; WATCHFUL WAITING; ACHIEVEMENT; MALE; ORGANIZATION AND MANAGEMENT; PROSTATIC NEOPLASMS; TRENDS; UROLOGY;

ACHIEVEMENT; CLINICAL TRIALS, PHASE III AS TOPIC; EUROPE; HUMANS; MALE; PROSTATIC NEOPLASMS; UROLOGY;

EID: 84926200114     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.076     Document Type: Article

References (45)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
3. A. Horwich, J. Hugosson, and T. de Reijke Prostate cancer: ESMO Consensus Conference guidelines 2012 Ann Oncol 24 2013 1141 1162
4. F.H. Schröder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
5. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
6. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
7. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
8. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
9. M.H. Bolla, van Poppel, and B. Tombal Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
10. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
11. E.A. Klein, I.M. Thompson Jr., and C.M. Tangen Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 306 2011 1549 1556
12. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
13. J.M. Crook, C.J. O'Callaghan, and G. Duncan Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
14. P. Warde, M. Mason, and K. Ding Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
15. H.J. de Voogt, M. Pavone-Macaluso, and P.H. Smith Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762 Prog Clin Biol Res 260 1988 111 117
16. M.R. Robinson, P.H. Smith, and B. Richards The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate Eur Urol 28 1995 273 283
17. L.J. Denis, F. Keuppens, and P.H. Smith Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center Eur Urol 33 1998 144 151
18. H.J. de Voogt, U. Studer, and F.H. Schröder Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organisation for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group Eur Urol 33 1998 152 158
19. F.H. Schroder, P. Whelan, and T.M. de Reijke Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892 Eur Urol 45 2004 457 464
20. S.D. Fossa, D. Curran, and N.K. Aaronson Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893 Eur Urol 37 2000 541 551
21. U.E.P. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876
22. U.E. Studer, L. Colette, and P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949
23. F.H. Schroder, K.H. Kurth, and S.D. Fossa Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial) Eur Urol 55 2009 14 22
24. P.O. Hedlund, H. Jacobsson, and S. Vaage Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 Study Group. Scandinavian Prostate Cancer Group Scand J Urol Nephrol 31 1997 167 172
25. T. Jørgensen, K.J. Tveter, and L.H. Jørgensen Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2 Eur Urol 24 1993 466 470
26. P.O. Hedlund, M. Ala-Opas, and E. Brekkan Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) study no. 5 Scand J Urol Nephrol 36 2002 405 413
27. P. Iversen, J.E. Johansson, and P. Lodding Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 study after a median follow-up period of 7.1 years Scand J Urol Nephrol 40 2006 441 452
28. M. Wirth, T. Tammela, and V. Cicalese Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) Eur Urol 67 2015 482 491
29. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma. Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5377
30. V. Beckendorf, S. Guérif, and E. Le Prisé 70 Gy vs 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomised trial Int J Radiat Oncol Biol Phys 80 2011 1056 1063
31. K. Fizazi, F. Lesaunier, and R. Delva A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial Eur J Cancer 48 2012 209 217
32. B. Dubray, V. Beckendorf, and S. Guerif Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer - intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741) [abstract 4521] J Clin Oncol 29 Suppl 2011
33. G. Gravis, K. Fizazi, and F. Joly Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 149 158
34. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
35. M.D. Mason, M.R. Sydes, and J. Glaholm Oral sodium clodronate for nonmetastatic prostate cancer - results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873) J Natl Cancer Inst 99 2007 765 776
36. D.P. Dearnaley, M.D. Mason, and M.K. Parmar Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
37. N.D. James, M.R. Sydes, and M.D. Mason Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Lancet Oncol 13 2012 549 558
38. N.D. James, S. Pirrie, and D. Barton Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747) [abstract LBA5000] J Clin Oncol 31 Suppl 2013
39. D. Bottke, R. Golz, and S. Störkel Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis Eur Urol 64 2013 193 198
40. T. Wiegel, D. Bartkowiak, and D. Bottke Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10 year follow-up of the ARO 96-02/AUO AP 09/95 trial Eur Urol 66 2014 243 250
41. K. Miller, U. Steiner, and A. Lingnau Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015] Proc Am Soc Clin Oncol 25 2007 238s
42. H.J. Meulenbeld, E.D. van Werkhoven, and J.L. Coenen Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) Eur J Cancer 48 2012 2993 3000
43. S. Ess, M. Joerger, and H. Frick Predictors of state-of-the-art management of early breast cancer in Switzerland Ann Oncol 22 2011 618 624
44. J.W. van de Loo, D. Trzaska, and K. Berkouk Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development Oncologist 17 2012 e26 e32
45. Horizon 2020: Support for researchers in Switzerland. Swiss Federal Administration News Web site. https://www.news.admin.ch/message/index.html?lang=en&msg-id=53516.